1. Search Result
Search Result
Results for "

non-small–cell lung cancer

" in MedChemExpress (MCE) Product Catalog:

679

Inhibitors & Agonists

2

Screening Libraries

8

Fluorescent Dyes

4

Biochemical Assay Reagents

6

Peptides

78

Inhibitory Antibodies

71

Natural
Products

19

Isotope-Labeled Compounds

1

Antibodies

8

Click Chemistry

8

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9903
    Nivolumab
    Maximum Cited Publications
    23 Publications Verification

    BMS-936558; ONO-4538; MDX-1106

    PD-1/PD-L1 Infection Cancer
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    Nivolumab
  • HY-P99269
    Sibrotuzumab
    1 Publications Verification

    BIBH 1; Anti-Human FAP Recombinant Antibody

    FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-P9964

    11F8; IMC-11F8; LY3012211

    EGFR Cancer
    Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
    Necitumumab
  • HY-148510

    Phosphatase Apoptosis Akt ERK Reactive Oxygen Species (ROS) Cancer
    HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 induces apoptosis. HKB99 inhibits the formation of invasive pseudopodia and inhibits migration. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) .
    HKB99
  • HY-13464

    Brigatinib analog

    Anaplastic lymphoma kinase (ALK) EGFR Cancer
    ALK-IN-1 is an orally active, blood-brain barrier-permeable ALK and EGFR inhibitor. ALK-IN-1 binds to and inhibits ALK kinase, ALK fusion proteins, and wild-type and mutant EGFR variants, thereby disrupting their corresponding signaling pathways. ALK-IN-1 can suppress the growth and proliferation of tumor cells and exhibits potential inhibitory activity against mutant EGFR. ALK-IN-1 can be used in the research of non-small-cell lung cancer .
    ALK-IN-1
  • HY-14907

    MPC 6827

    Microtubule/Tubulin Cancer
    Verubulin (MPC-6827) is a highly potent and broad-spectrum microtubule blocker. Verubulin has antitumor activity against breast cancer, melanoma, and ovarian cancer. Verubulin can be used in non-small cell lung cancer research .
    Verubulin
  • HY-P99202

    Transmembrane Glycoprotein Cancer
    Vibostolimab is an anti-TIGIT (T cell immunoglobulin and ITIM domain) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small cell lung cancer (NSCLC) and melanoma research .
    Vibostolimab
  • HY-P990042

    ONC-392; BNT 316

    CTLA-4 Inflammation/Immunology Cancer
    Gotistobart (ONC-392; BNT 316) is a humanized anti-CTLA-4 antibody with selective regulatory T cell depletion activity in the tumor microenvironment. Gotistobart can be used for the research of cancer, such as non-small cell lung cancer .
    Gotistobart
  • HY-168054

    PROTACs Ras Cancer
    PROTAC K-Ras Degrader-3 (compound 40) is a PROTAC degrader of K-Ras with a DC50 of ≤ 1 nM against SW620 KRAS G12D, and a GI50 of ≤ 10 nM against SW620 3D cell growth. PROTAC K-Ras Degrader-3 can be utilized in cancer research, such as non-small-cell lung cancer (NSCLC) .
    PROTAC K-Ras Degrader-3
  • HY-12972

    PF-06747775

    EGFR Cancer
    Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC50s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC) .
    Mavelertinib
  • HY-P990704

    AZD-2936

    PD-1/PD-L1 Transmembrane Glycoprotein Cancer
    Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting PD-1 and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .
    Rilvegostomig
  • HY-118263
    Dacomitinib hydrate
    25+ Cited Publications

    PF-00299804 hydrate; PF-299804 hydrate

    EGFR Cancer
    Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .
    Dacomitinib hydrate
  • HY-160715

    Toll-like Receptor (TLR) Cancer
    BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC) .
    BNT411
  • HY-P99223

    MEDI-575

    PDGFR Cancer
    Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .
    Tovetumab
  • HY-P99858

    AB154

    Transmembrane Glycoprotein Cancer
    Domvanalimab (AB154) is an anti-TIGIT humanized monoclonal antibody. Domvanalimab binds human TIGIT9 and blocks the TIGIT-CD155 interaction. Domvanalimab can be used for studies of non-small cell lung cancer and esophageal cancer .
    Domvanalimab
  • HY-113418

    Endogenous Metabolite Cancer
    Beta-Cortol is an O-glycosylated compound and cortisol metabolite. It can be isolated from the leaves of mulberry cultivar Yu 711, and its concentration decreases significantly when the plant is subjected to drought stress. Beta-Cortol serves as a biomarker, as serum Beta-Cortol levels in early non-small cell lung cancer models are downregulated to 1/8 of the preoperative level after tumor resection. Due to such dramatic changes under specific pathological conditions, Beta-Cortol is currently widely used in studies related to early non-small cell lung cancer .
    Beta-Cortol
  • HY-162753

    P-glycoprotein Cancer
    ZW-1226 is a dual Tyrosyl DNA phosphodiesterase 2 (TDP2) and Multidrug resistance-associated protein 1 (MRP1) inhibitor with IC50 values of 0.2 and 0.5 μM, respectively. ZW-1226 exhibits selectivity over other ABC transporters. ZW-1226 elevates intracellular GSH levels, and reverses MRP1-mediated drug resistance. ZW-1226 can be used for the research of leukemia, non-small-cell lung cancer, and multidrug resistant small-cell lung cancer .
    ZW-1226
  • HY-168566

    HSP Cancer
    EV206 is a Hsp70 binder and apoptosis inducer that binds to the N-terminal domain of Hsp70, promotes Hsp70 degradation via the ubiquitin-proteasome system, and reduces Hsp70 protein stability. EV206 induces apoptotic cell death, inhibits colony formation, and downregulates the expression of cancer stem cell-related markers in non-small cell lung cancer cells. EV206 inhibits the growth of H460 xenograft tumors in nude mice and can be used for the research of non-small cell lung cancer .
    EV206
  • HY-148803

    c-Met/HGFR Cancer
    Vabametkib is a MET TKI inhibitor. Vabametkib can be used in research on non-small cell lung cancer (NSCLC) .
    Vabametkib
  • HY-124321

    CDK Cancer
    Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .
    Metralindole hydrochloride
  • HY-13617

    CGP 30694

    Antifolate Cancer
    Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .
    Edatrexate
  • HY-142283AS

    AZD-9291-d5 mesylate; Mereletinib-d5 mesylate

    EGFR Cancer
    Dosimertinib-d5 (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d5 (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d5 (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d5 (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC) .
    Dosimertinib-d5 mesylate
  • HY-19637

    Topoisomerase Cancer
    SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.
    SW044248
  • HY-110335

    ROCK Cancer
    OXA-06 hydrochloride is an ATP-competitive ROCK inhibitor that blocks anchorage-dependent growth and invasion of non-small cell lung cancer cell lines. OXA-06 hydrochloride inhibits cofilin phosphorylation but does not stimulate apoptosis .
    OXA-06 hydrochloride
  • HY-138072

    EGFR Cancer
    EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) .
    EMI1
  • HY-142283

    Isotope-Labeled Compounds EGFR Cancer
    Dosimertinib-d3-d3 is a potent and orally active EGFR inhibitor. Dosimertinib-d3-d3 decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d3-d3 shows antiproliferative and anti-tumor activity. Dosimertinib-d3-d3 has the potential for the research of non-small-cell lung cancer (NSCLC) .
    Dosimertinib
  • HY-148053

    Drug Metabolite Cancer
    Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer .
    Rezivertinib analogue 1
  • HY-172237

    Ras Cancer
    Sosimerasib is an orally active KRAS G12C inhibitor. Sosimerasib can be used in research related to non-small cell lung cancer .
    Sosimerasib
  • HY-13554

    Antibiotic Cancer
    Annamycin is an anthracycline antibiotic with antitumor activity. Annamycin interacts with topoisomerase II, induces double-strand DNA breaks, triggers cell death, and exerts cytotoxic effects. In mice, Annamycin inhibits the growth of advanced subcutaneous melanoma and subcutaneous squamous cell carcinoma, and prolongs the survival of mice with subcutaneous reticulosarcoma and in lung cancer lung metastasis models. Annamycin can be used in research related to melanoma, reticulum cell sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer .
    Annamycin
  • HY-149842

    Akt Apoptosis Cancer
    AKT-IN-18, an inhibitor of Akt, inhibits Akt with an IC50 of 69.45 μΜ in A549 cells. AKT-IN-18 induces apoptosis and can be used in non-small cell lung cancer study .
    AKT-IN-18
  • HY-164487

    Proteasome Cancer
    JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .
    JBJ-08-178-01
  • HY-163418

    EGFR Cancer
    HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC50 <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC50 <200 nM and amliorates non-small-cell lung cancer (NSCLC) .
    HER2-IN-17
  • HY-175009

    EGFR JAK STAT Apoptosis Cancer
    MRC-G-001 is a Genipin (HY-17389) derivative with an IC50 of 117 μM against A549 cancer cells. MRC-G-001 inhibits the phosphorylation of EGFR, JAK1, and STAT3, and modulates epithelial-mesenchymal transition (EMT)-related protein expression, thereby attenuating cell migration and invasion. MRC-G-001 induces cell cycle arrest and cell apoptosis. MRC-G-001 can be used for the study of cancers such as non-small-cell lung cancer .
    MRC-G-001
  • HY-169741

    Discoidin Domain Receptor Cancer
    DDR1-IN-10 (compound 7q) is a DDR1 inhibitor. DDR1-IN-10 can be used in the study of pancreatic cancer, non-small cell lung cancer, and gastric carcinoma .
    DDR1-IN-10
  • HY-N16565

    Others Cancer
    Piperchabamide B is an amide alkaloid. Piperchabamide B can be isolated from the fruits of Piper longum. Piperchabamide B exhibits anticancer activity against acute promyelocytic leukemia, non-small cell lung cancer, and breast cancer .
    Piperchabamide B
  • HY-P991635

    TNF Receptor Cancer
    PF-07329640 is a humanized monoclonal antibody inhibitor targeting TNFRSF3. PF-07329640 can be used for advanced/metastatic solid tumors like non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) research .
    PF-07329640
  • HY-119182
    Mitonafide
    2 Publications Verification

    NSC 300288

    DNA/RNA Synthesis Cancer
    Mitonafide (NSC 300288) is a cytostatic agent. Mitonafide binds to double-stranded DNA through intercalation, and inhibits DNA and RNA synthesis. Mitonafide is an antitumor agent that can be used in the research of cancers, such as non-small cell lung cancer (NSCLC), leukemia .
    Mitonafide
  • HY-176870

    Ras Cancer
    KRAS-IN-42 (Compound Z1063) is a covalent KRAS G12D mutants inhibitor. KRAS-IN-42 is promising for research of KRAS G12D-mutant cancers (e.g., non-small cell lung cancer, colorectal cancer) .
    KRAS-IN-42
  • HY-157912

    EGFR Cancer
    EGFR-IN-102 (compound 6) is an oral active EGFR inhibitor with the IC50 of 2 nM, and can be used for study of non-small-cell lung cancer .
    EGFR-IN-102
  • HY-164464

    EGFR Cancer
    BPI-15086 an orally active, potent, irreversible mutant-selective inhibitor of both EGFR and T790M resistance mutations tyrosine kinase. BPI-15086 can be used for the research of non-small-cell lung cancer .
    BPI-15086
  • HY-167948

    EGFR Cancer
    Dacomitinib metabolite M1/2 is a potent inhibitor of both wild-type (WT) EGFR and the T790M mutation, demonstrating significant activity against acquired resistance mechanisms in EGFR-mutant non-small-cell lung cancer (NSCLC).
    Dacomitinib metabolite M1/2
  • HY-145844

    EGFR Apoptosis Cancer
    EGFR-IN-44 (Compound 6a) is a potent, orally active EGFR tyrosine kinase inhibitor with an IC50 of 4.11 nM. EGFR-IN-44 induces cell apoptosis and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers .
    EGFR-IN-44
  • HY-14389

    Microtubule/Tubulin Cancer
    LP-261 is a potent and orally active anti-mitotic agent and shows an inhibition of in vitro tubulin polymerization with an EC50 of 3.2 μM . LP-261 inhibits growth of a human non-small-cell lung tumor (NCI-H522) in vivo and can be used for cancer research .
    LP-261
  • HY-154960

    Akt Apoptosis Microtubule/Tubulin Cancer
    Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and AKT pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research .
    Tubulin/AKT1-IN-1
  • HY-168112

    EGFR Cancer
    EGFR-IN-127 is an ATP-competitive EGFR inhibitor with IC50s of 136.3 nM and 161. 2 nM for EGFR del19 and EGFR del19/T790M/C797S, respectively. EGFR-IN-127 has the potential for the study of non-small-cell lung cancer (NSCLC) .
    EGFR-IN-127
  • HY-163417

    EGFR Cancer
    HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC50 <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC50 <200 nM and amliorates non-small-cell lung cancer (NSCLC) .
    HER2-IN-15
  • HY-163420

    EGFR Cancer
    HER2-IN-16 (Compound 14) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC50 <200 nM. HER2-IN-16 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC50 <200 nM and amliorates non-small-cell lung cancer (NSCLC) .
    HER2-IN-16
  • HY-173500

    MMP Apoptosis EGFR STAT Cancer
    MG-3C is a potent matrix metalloproteinase 9 (MMP-9) inhibitor. MG-3C can selectively kill non-small-cell lung cancer (NSCLC) cells harboring the EGFR T790M mutation. MG-3C blocks the EGFR/STAT3 signaling pathway, inducing G2/M phase arrest, growth inhibition, and apoptosis of cancer cells. MG-3C is promising for research of lung cancer .
    MG-3C
  • HY-W110138

    DNA/RNA Synthesis Cytochrome P450 ROCK Cancer
    Chloroxoquinoline is an anticancer agent. Chloroxoquinoline damages the DNA templates of cancer cells, inducing DNA breaks and cell death, and inhibits cell invasion via down-regulating Rho/Rho kinase signaling pathway. Chloroxoquinoline enhances the radiation sensitivity of Lewis lung cancer cells and xenograft tumors in tumor-bearing mouse models but decreases efficacy after long term exposure in rat models by auto-induction effects on CYP1A and CYP3A. Chloroxoquinoline has a broad-spectrum anticancer activity, such as non-small-cell lung carcinoma (NSCLC), breast cancer and gastric cancer .
    Chloroxoquinoline
  • HY-173460

    Ras Cancer
    RAS-IN-3 (compound 22) is a potent Ras inhibitor. ROCK-IN-12 can be used in the study of Non-small cell lung cancer and colorectal cancer .
    RAS-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: